History of BIA-ALCL In 2011, the Food and Drug Administration (FDA) reported 34 cases worldwide of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), bringing this unique disease into the public eye for the first time. Since then, BIA-ALCL has been recognized internationally as a distinct type of cancer, and prompted the 2019 … [Read more...]
Breast Implants Lymphoma Cancer Cases Update February 2019 – US & Canada
In February 2019 the FDA announced that it has received a total of 660 medical device reports (MDRs) regarding breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), cases in the United States since 2010. This new total indicates an increase of about 246 new reports of breast implants lymphoma cancer cases in the past year. According … [Read more...]
Several 2018 Breast Implant Lymphoma Cancer Lawsuits Already Filed
Background Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a type of non-Hodgkin's lymphoma, which is a cancer of the cells of the immune system. This rare T-cell lymphoma can develop as a result of breast implants, though the mechanism of injury is not fully understood at this time. However, based on current data from the … [Read more...]
FDA Provides Updated Number of Breast Implants Lymphoma Cancers
About BIA-ALCL The U.S. Food and Drug Administration (FDA) has been aware of the possible connection between breast implants and breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) since 2011. This condition is a rare type of non-Hodgkin’s lymphoma, which is a cancer of the immune system, rather than a cancer of the breast … [Read more...]